DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Dopamine and Insulin Resistance

Information source: Vanderbilt University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Obesity

Intervention: PET scan (Radiation); Oral glucose tolerance test (Procedure); MRI (Procedure); Psychological scales to assess attitudes and behaviors related to eating and quality of life (Behavioral); Caloric Restriction (Other)

Phase: N/A

Status: Recruiting

Sponsored by: Vanderbilt University

Official(s) and/or principal investigator(s):
Julia P Dunn, MD, Principal Investigator, Affiliation: Vanderbilt University
Robert M Kessler, MD, Study Director, Affiliation: Vanderbilt University

Overall contact:
Pamela A Marks, MS, RD, Phone: 615-343-8389, Email: pamela.a.marks@vanderbilt.edu

Summary

Obese individuals have fewer striatal dopamine type 2 receptors (DRD2) than normal weight individuals. Lower DRD2 levels are associated with addiction and a decreased sense of pleasure. Obesity is also associated with insulin resistance (poor insulin action).We propose that insulin resistance and low DRD2 are associated. Using PET imaging,we aim to determine DRD2 binding potential (BP) in the brain is associated with insulin resistance and neuroendocrine hormone levels. Obese participants will be compared to lean, gender and age similar participants. We also aim to determine the effect of caloric restriction on DRD2 BP in obese subjects

Clinical Details

Official title: Dopamine and Insulin Resistance

Study design: Intervention Model: Single Group Assignment, Masking: Open Label

Primary outcome: Are fasting neuroendocrine hormones and insulin sensitivity associated with DRD2 receptor binding?

Secondary outcome:

Are certain eating behaviors associated with DRD2 binding?

Does caloric restriction alter DRD2 DP in obese participants?

Eligibility

Minimum age: 18 Years. Maximum age: 60 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Ages 18-60 yrs

- obese BMI > 30kg/m2 and Weight less than 350 lbs

- lean control BMI 18-25kg/m2

Exclusion Criteria:

- Structured exercise > equivalent to 30mins 5x week of walking times a week

- History of Substance Abuse, including but exclusive to alcohol, cocaine, marijuana,

heroin, nicotine

- Current psychiatric disorder or significant h/o disorder

- Use or any antidepressants or antipsychotics for last 3-6months or depot

antipsychotics in the last 12 months

- Any condition felt by PI or co-investigators to interfere with ability to complete

the study

- Inability to abstain from alcohol, physical exercise or > 1 cup of coffee or

equivalent daily for 3 days prior to imaging studies

- Significant co-morbidities including atherosclerotic disease, metabolic disease,

liver or renal insufficiency or abnormality found on MRI

- Any condition which would interfere with MRI or PET studies, e. g. claustrophobia,

cochlear implant, metal fragments in eyes, cardiac pacemaker, neural stimulator, tattoos with iron pigment and metallic body inclusions or other metal implanted in the body which may interfere with MRI scanning

- Subjects on medications determined by PI, ex. sibutramine, frequent benzodiazepines

or related drugs, which could affect quality of study for last 3 months.

Locations and Contacts

Pamela A Marks, MS, RD, Phone: 615-343-8389, Email: pamela.a.marks@vanderbilt.edu

Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States; Recruiting
Marks, Email: obesityresearch@vanderbilt.edu
Julia P Dunn, MD, Principal Investigator
Additional Information

Starting date: December 2008
Last updated: February 14, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017